Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study

Diamant Thaçi; Lluís Puig; Kristian Reich; Tsen-Fang Tsai; Stephen Tyring; Külli Kingo; Michael Ziv; Andreas Pinter; Ronald Vender; Aude Lacombe; Summer Xia; Vaishali Bhosekar; Isabelle Gilloteau; Adriana Guana; Andrew Blauvelt

doi:10.1016/j.jaad.2019.04.045

Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.04.045 ◽

2019 ◽

Vol 81 (6) ◽

pp. 1405-1409 ◽

Cited By ~ 2

Author(s):

Diamant Thaçi ◽

Lluís Puig ◽

Kristian Reich ◽

Tsen-Fang Tsai ◽

Stephen Tyring ◽

...

Keyword(s):

Patient Reported Outcomes ◽

Severe Psoriasis ◽

Treatment Results ◽

Sustained Efficacy ◽

Patient Reported

Download Full-text

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.12081 ◽

2013 ◽

Vol 28 (2) ◽

pp. 192-203 ◽

Cited By ~ 38

Author(s):

C. Mamolo ◽

J. Harness ◽

H. Tan ◽

A. Menter

Keyword(s):

Patient Reported Outcomes ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Controlled Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Patient Reported

Download Full-text

14030 Ten-year interim results from the ESPRIT registry: Real-world safety, effectiveness, and patient-reported outcomes of adalimumab for moderate to severe psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.155 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB17

Author(s):

Jashin J. Wu ◽

William Abramovits ◽

Wendell C. Valdecantos ◽

Ofelia Reyes Servin ◽

Mareike Bereswill ◽

...

Keyword(s):

Real World ◽

Patient Reported Outcomes ◽

Severe Psoriasis ◽

Patient Reported ◽

Safety Effectiveness

Download Full-text

ESPRIT registry nine-year interim real-world safety, effectiveness, and patient-reported outcomes of adalimumab for moderate to severe psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.758 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB206

Keyword(s):

Real World ◽

Patient Reported Outcomes ◽

Severe Psoriasis ◽

Patient Reported ◽

Safety Effectiveness

Download Full-text

Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis

JAMA Dermatology ◽

10.1001/jamadermatol.2020.3617 ◽

2020 ◽

Vol 156 (12) ◽

pp. 1344

Author(s):

Matthias Augustin ◽

Jo Lambert ◽

Carla Zema ◽

Elizabeth H. Z. Thompson ◽

Min Yang ◽

...

Keyword(s):

Patient Reported Outcomes ◽

Severe Psoriasis ◽

Patient Reported

Download Full-text

PSS28 Long-Term Improvement in Patient-Reported Outcomes After Transition From Methotrexate to Ustekinumab in Moderate to Severe Psoriasis: Transit Week 52 Results

Value in Health ◽

10.1016/j.jval.2012.08.2075 ◽

2012 ◽

Vol 15 (7) ◽

pp. A573

Author(s):

K. Reich ◽

L. Puig ◽

T. Luger ◽

J. Lambert ◽

S. Chimenti ◽

...

Keyword(s):

Patient Reported Outcomes ◽

Severe Psoriasis ◽

Patient Reported

Download Full-text

EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs)

Annals of Oncology ◽

10.1093/annonc/mdx671.009 ◽

2017 ◽

Vol 28 ◽

pp. x127-x128

Author(s):

R. Soo ◽

T.S.K. Mok ◽

Y-K Shi ◽

L. Zhang ◽

S. Lu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Patient Reported Outcomes ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Treatment Results ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Patient Reported

Download Full-text

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

Health and Quality of Life Outcomes ◽

10.1186/1477-7525-11-82 ◽

2013 ◽

Vol 11 (1) ◽

pp. 82 ◽

Cited By ~ 33

Author(s):

Vibeke Strand ◽

David Fiorentino ◽

ChiaChi Hu ◽

Robert M Day ◽

Randall M Stevens ◽

...

Keyword(s):

Patient Reported Outcomes ◽

Severe Psoriasis ◽

Randomized Controlled Study ◽

Controlled Study ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Patient Reported ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study

BMC Pulmonary Medicine ◽

10.1186/s12890-019-0887-6 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 4

Author(s):

Scott C. Bell ◽

Jochen G. Mainz ◽

Gordon MacGregor ◽

Susan Madge ◽

Julie Macey ◽

...

Keyword(s):

Cystic Fibrosis ◽

Patient Reported Outcomes ◽

Cross Sectional Study ◽

Sectional Study ◽

Treatment Results ◽

Cross Sectional ◽

Patient Reported

Download Full-text

The benefits of adalimumab on clinical and patient-reported outcomes among moderate to severe psoriasis patients with comorbidities

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2008.11.425 ◽

2009 ◽

Vol 60 (3) ◽

pp. AB95 ◽

Cited By ~ 1

Keyword(s):

Patient Reported Outcomes ◽

Severe Psoriasis ◽

Patient Reported

Download Full-text

Static Physicians Global Assessment (sPGA) of 0 or 1 is associated with improved patient reported outcomes in patients with moderate to severe psoriasis in a phase 2 trial of ixekizumab

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.787 ◽

2014 ◽

Vol 70 (5) ◽

pp. AB190

Keyword(s):

Global Assessment ◽

Patient Reported Outcomes ◽

Severe Psoriasis ◽

Phase 2 ◽

Phase 2 Trial ◽

Patient Reported

Download Full-text